Please assess the completion status of the following clinical trial:

Trial Title: Cilostazol Augmentation Study in Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men/women over sixty years old~* Patients with slight and moderate dementia (MMSE score is over 10 under 26.)~* Patients with probable Alzheimer's disease according to the standard of NINCDS-ADRDA~* Patients accompanied with WMHI on Brain MRI (Fazeka's scale 1\~3)~Exclusion Criteria:~* Those who do not agree to the test in a written form~* Patients who accompany other diseases except cerebral atrophy or change of subcortical white matter due to Alzheimer's disease on brain MRI~* Patients who should not use Cilostazol (① patients with bleeding tendency ② patients with congestive heart failure ③ patients who have a medical history of hypersensitivity to this medicine or constituent of this medicine ④ those who use anticoagulant and clot buster)~* Patients who suffer from nerve diseases or mental diseases which have influence on cognitive function except Alzheimer's disease (for example, schizophrenia, severe depression, mental retardation and etc.)~* Patients who are suspected to have a personal history of drug addiction or alcoholism within recent 10 years~* Patients who have severe problems in eye sight or hearing so that it is impossible to conduct the test smoothly~* Patients who the researchers think are inappropriate for taking part in the test

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cilostazol (Type: EXPERIMENTAL): Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group means dementia patients group receiving donepezil with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).